Given the heterogeneity in study design, populations, intervention duration, and clinical endpoints, findings were interpreted with careful consideration of variability across the evidence base
J Gastrointest Liver Dis JGLD 27(1):3139
Sanjay Kaul, a frequent FDA advisor, pointed out the paradox of the large commercial success of the diabetes drugs despite the absence of any proven clinical benefit: "So, we have a drug that yields modest glycemic efficacy, is neutral with respect to cardiometabolic factors (lipids, weight, blood pressure), does not kill you or land you in a hospital, and yet is a blockbuster drug nearly 5 times over
GHB withdrawal resembles alcohol withdrawal but can begin more rapidly because of GHBs short half-life
This case highlights the need for immediate initiation of ATRA in APL patients, even before genetic confirmation, and the potential therapeutic role of ATO in both leukemia treatment and HIV reservoir management
However, it was withdrawn in the 1960s due to reported renal and hepatic toxicities
